Innovus gets new canadian patent for Zestra

It is the first patent granted for Zestra in Canada and is valid until June 2021, while it is the tenth patent that the company’s wholly-owned subsidiary, Semprae Laboratorieshas been issued across the world.

Innovus Pharmaceuticals president and chief executive officer Bassam Damaj said the issuance of this patent for compositions and methods for treating sexual response increases our worldwide patent portfolio in the female sexual dysfunction field.

"In addition, the ‘552 Patent provides Innovus Pharma with patent protection for Zestra, which to the Company’s knowledge, is only over-the-counter (OTC) product approved in Canada for such a large indication," Damaj said.

Zestra is the only OTC natural product clinically proven in two US double-blind, placebo controlled trials carried out in 276 women to increase arousal and desire during sexual intercourse.

It is the first NHP product to receive approval for the indication of FSDD in Canada, which is a subset of Female Sexual Disorder (FSD) that also includes Female Sexual Arousal Disorder (FSAD).

So far, no product has been approved in the US and Canada to treat FSAD or FSDD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity.

Innovus had recently announced that it filed for the Female Sexual Interest/Arousal Disorder (FSI/AD) expanded label indication for its marketed Zestra product with Health Canada.

Currently, Zestra is approved and marketed in Canada for the indication of Temporary Increase of Desire in Female Sexual Desire Disorder Women (FSDD).